Related Experiment Video
Updated: Aug 21, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Andamertinib: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
None:
Andamertinib (®) is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) being developed by Beijing Avistone Biotechnology for the treatment of non-small cell lung cancer (NSCLC). On 30 April 2026, andamertinib received conditional approval in China for adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or following platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and who have been confirmed by testing to have an EGFR exon 20 insertion mutation. This article summarizes the milestones in the development of andamertinib leading to this first approval for NSCLC.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
